Momentum is building to reevaluate the safety of pain relievers like Celebrex and Vioxx due to concerns about heart problems.
Researchers warn that these drugs may block substances that prevent heart issues.
The FDA is criticized for not investigating Vioxx's heart risks sooner.
Merck withdrew Vioxx from the market after discovering increased heart risks.
The FDA's hands-off approach to drug safety is questioned.
Concerns about cardiovascular risks associated with Vioxx and Celebrex are raised.
The withdrawal of Vioxx prompts scrutiny of drug safety monitoring practices.
